XORTX Therapeutics Inc. (V:XRX)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Dec 10, 2021 07:01 am ET

XORTX Therapeutics Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to highlight and...

Dec 09, 2021 08:03 am ET

XORTX Announces Research Coverage Initiated by A.G.P./Alliance Global Partners

Dec 02, 2021 07:00 am ET

XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study

Nov 23, 2021 07:00 am ET

XORTX Therapeutics Announces Annual and Special Meeting of Shareholders

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces that it will hold its annual and special...

Nov 09, 2021 07:00 am ET

XORTX Therapeutics Announces Partial Exercise of Over-Allotment Option Pursuant to US Public Offering

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, today announced that it has issued an additional...

Nov 04, 2021 02:48 pm ET

XORTX Therapeutics Clarifies Halt of Trading in Canada and Timing for Commencement of Trading on TSX Venture Exchange

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, wishes to clarify that the Company’s common shares...

Nov 04, 2021 02:11 pm ET

CSE Bulletin: Delist - XORTX Therapeutics Inc. (XRX)

Toronto, Ontario--(Newsfile Corp. - le 4 novembre/November 2021) At the request of the company the common shares of XORTX Therapeutics Inc. will be delisted at market close on November 4, 2021.

Nov 04, 2021 08:21 am ET

IIROC Trading Halt - XRX

VANCOUVER, BC, Nov. 4, 2021 /CNW/ - The following issues have been halted by IIROC:

Nov 02, 2021 06:13 pm ET

XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has received final...

Oct 15, 2021 05:38 pm ET

XORTX Therapeutics Announces Closing of US$12 Million Public Offering

Oct 14, 2021 05:30 pm ET

XORTX Announces Results from Mount Sinai’s COVID-19 Clinical Study

Oct 14, 2021 07:00 am ET

XORTX to Present at the LD Micro Main Event

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the LD Micro Main...

Oct 13, 2021 07:55 am ET

XORTX Therapeutics Announces Pricing of US$12 Million Public Offering and Nasdaq Listing

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces the pricing of an underwritten public...

Sep 21, 2021 12:49 pm ET

CSE Bulletin: Consolidation - XORTX Therapeutics Inc. (XRX)

Toronto, Ontario--(Newsfile Corp. - Le 21 septembre/September 2021) - XORTX Therapeutics Inc. has announced a consolidation of its issued and outstanding common shares on the basis of 1 post-consolidation common share for every 11.74 pre-consolidation common shares.

Sep 20, 2021 04:46 pm ET

XORTX Therapeutics Announces Share Consolidation

Sep 02, 2021 02:26 pm ET

XORTX Therapeutics Reports Special Meeting Results

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of the Company’s...

Sep 01, 2021 07:00 am ET

XORTX Announces Grant of European Patent

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biotechnology company focused on developing therapeutics for the treatment of progressive kidney disease, is pleased to advise that further to its press release of...

Aug 31, 2021 09:11 am ET

XORTX Announces New Clinical Advisory Board Member

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biotechnology company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the addition of one new member to the...

Aug 13, 2021 05:00 pm ET

XORTX Therapeutics Calls Special Meeting of Shareholders

Jul 14, 2021 07:00 am ET

XORTX Therapeutics Strengthens Executive Team

Jun 30, 2021 07:00 am ET

Dr. Stephen Haworth Joins XORTX Management Team

Jun 17, 2021 07:00 am ET

XORTX Welcomes Jaqueline Le Saux to Board of Directors

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biotechnology company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Jacqueline Le Saux to the...

May 13, 2021 07:00 am ET

XORTX Welcomes New Member to Board of Directors

Apr 06, 2021 07:00 am ET

XORTX Announces Notice to Grant European Patent

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing therapeutics for the treatment of progressive kidney disease, is pleased to announce that it has received notification...

Mar 16, 2021 09:15 am ET

XORTX to Present at "Zoom With LD MICRO"

CALGARY, AB / ACCESSWIRE / March 16, 2021 / XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the Zoom with LD Mirco to be held virtually on March 18, 2021.

Mar 16, 2021 07:00 am ET

XORTX to Present at “Zoom With LD MICRO”

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the Zoom with LD Mirco to be...

Mar 09, 2021 08:35 am ET

XORTX to Present and Participate in the Sachs 14th Annual European Life Sciences CEO Forum 2021

CALGARY, AB / ACCESSWIRE / March 9, 2021 / XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE:XRX)(OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the Sachs 14th Annual European Life Sciences CEO Forum 2021 to be held virtually March 10th and 11th, 2021.

Mar 09, 2021 07:00 am ET

XORTX to Present and Participate in the Sachs 14th Annual European Life Sciences CEO Forum 2021

Mar 08, 2021 09:45 am ET

XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

Compositions and Methods for Enhancing Anti-viral Therapies

Mar 08, 2021 09:12 am ET

XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, with late-stage clinical programs, is pleased to announce the...

Mar 02, 2021 07:00 am ET

XORTX Confirms $1 Million in Warrant Exercise Proceeds

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that 4,286,438 warrants that were issued...

Mar 01, 2021 07:00 am ET

XORTX Participating in WuXI Healthcare Forum

Feb 17, 2021 07:00 am ET

XORTX to Present at BIO CEO and Investor Conference

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that the Company is participating in the BIO CEO and...

Feb 10, 2021 07:00 am ET

XORTX Closes Over Subscribed Private Placement

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed the over-subscribed...

Feb 08, 2021 07:40 am ET

XORTX Announces Over Subscribed Private Placement

CALGARY, AB / ACCESSWIRE / February 8, 2021 / XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE:XRX)(OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that further to its press release of January 28th, the Company is further increasing the private placement due to the high level of interest. The Company will now issue 24,486,286 units (the "Units"), priced at $0.25 per Unit for total gr

Feb 08, 2021 07:00 am ET

XORTX Announces Over Subscribed Private Placement

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that further to its press release of...

Jan 28, 2021 07:00 am ET

XORTX Announces Increase to Private Placement

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that further to its press release of...

Jan 19, 2021 10:10 am ET

XORTX Provides Corporate Update; Synopsis of 2020 Achievements and Key Activities for 2021

CALGARY, AB / ACCESSWIRE / January 19, 2021 / XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide a synopsis of 2020 achievements and guidance on key activities for 2021.

Jan 19, 2021 06:55 am ET

XORTX Provides Corporate Update

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide a synopsis of 2020 achievements and...

Jan 12, 2021 07:00 am ET

XORTX Grants Options

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has granted in accordance with the Company’s...

Jan 07, 2021 06:33 pm ET

XORTX Announces Private Placement

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces a non-brokered private placement to raise between CDN...

Dec 29, 2020 07:00 am ET

XORTX Announces Grant of European Patent

Nov 16, 2020 08:54 am ET

XORTX Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study

Nov 16, 2020 08:16 am ET

IIROC Trade Resumption - XRX

VANCOUVER, BC, Nov. 16, 2020 /CNW/ - Trading resumes in:

Nov 16, 2020 07:40 am ET

IIROC Trading Halt - XRX

VANCOUVER, BC, Nov. 16, 2020 /CNW/ - The following issues have been halted by IIROC:

Oct 28, 2020 11:35 am ET

XORTX Participation in Virtual Conferences

Oct 23, 2020 06:34 pm ET

XORTX Reports Annual & Special Meeting Results

Oct 08, 2020 10:28 am ET

IIROC Trade Resumption - XRX

VANCOUVER, BC, Oct. 8, 2020 /CNW/ - Trading resumes in:

Oct 08, 2020 10:21 am ET

IIROC Trading Halt - XRX

VANCOUVER, BC, Oct. 8, 2020 /CNW/ - The following issues have been halted by IIROC:

Oct 08, 2020 10:14 am ET

XORTX Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a clinical stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company has...

Sep 15, 2020 07:00 am ET

XORTX Highlights New Studies of Acute Kidney Disease Due to COVID-19 Infection

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, highlights newly published information related to COVID-19...

Aug 31, 2020 07:00 am ET

XORTX Files U.S. FDA Pre-IND Meeting Request for XRx-101 (Oxypurinol) COVID-19 Program and Pre-IND Meeting Submission

XORTX Therapeutics Inc. (CSE : XRX) (OTCQB : XRTXF) (FRANKFURT : ANU1) (the “Company” or “XORTX”) a late clinical stage pharmaceutical development company focused on kidney disease, is pleased to announce that the Company has filed its pre-IND...

Aug 28, 2020 06:38 pm ET

XORTX Announces Change to Board of Directors

XORTX Therapeutics Inc. (CSE : XRX) (OTCQB : XRTXF) (FRANKFURT : ANU1) (the “Company” or “XORTX”) a late clinical stage pharmaceutical development company focused on kidney disease, is pleased announce that Ian Klassen will join the XORTX board of...

Aug 07, 2020 07:00 am ET

XORTX Appoints Dr. David Sans in New York as Director Corporate Development

Aug 04, 2020 11:11 am ET

IIROC Trade Resumption - XRX

VANCOUVER, BC, Aug. 4, 2020 /CNW/ - Trading resumes in:

Aug 04, 2020 10:11 am ET

XORTX Partners with Mount Sinai’s Icahn School of Medicine on US-based Clinical Trial in COVID-19

Aug 04, 2020 09:49 am ET

IIROC Trading Halt - XRX

VANCOUVER, BC, Aug. 4, 2020 /CNW/ - The following issues have been halted by IIROC:

Jun 23, 2020 07:00 am ET

XORTX Announces Mr. Anthony J. Giovinazzo to Join as Special Advisor to the Board of Directors

May 19, 2020 09:38 am ET

XORTX Provides Program Update Regarding XRx-008 for ADPKD and XRx-101 for Coronavirus / COVID-19 Programs

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF) (FRANKFURT: ANU1), a biopharmaceutical company focused on developing innovative therapies to treat kidney disease, is pleased to provide the following update on its...

Apr 30, 2020 09:15 am ET

IIROC Trade Resumption - XRX

VANCOUVER, April 30, 2020 /CNW/ - Trading resumes in:

Apr 30, 2020 09:02 am ET

XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus / COVID-19 Clinical Trials

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF) (FRANKFURT: ANU1), a biopharmaceutical company focused on developing innovative therapies to treat kidney disease announces that it has granted the manufacturing contract...

Apr 30, 2020 08:48 am ET

IIROC Trading Halt - XRX

VANCOUVER, April 30, 2020 /CNW/ - The following issues have been halted by IIROC:

Apr 30, 2020 08:30 am ET

XORTX Provides Overview and Update of Key Activities

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, confirms that the Company has filed its audited financial...

Mar 26, 2020 07:00 am ET

XORTX Announces New Clinical Advisory Board Member

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat polycystic kidney disease (PKD), is pleased to announce that Dr. Anjay Rastogi has joined...

Mar 16, 2020 11:35 am ET

IIROC Trade Resumption - XRX

VANCOUVER, March 16, 2020 /CNW/ - Trading resumes in:

Mar 16, 2020 11:00 am ET

XORTX Launches XRx-101 Following the Filing of a Provisional Patent to Potentially Treat Respiratory and Kidney Disease Injury Due to Coronavirus Infection

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, with late stage clinical programs, is re-issuing its earlier...

Mar 16, 2020 09:18 am ET

IIROC Trading Halt - XRX

VANCOUVER, March 16, 2020 /CNW/ - The following issues have been halted by IIROC:

Mar 16, 2020 07:00 am ET

XORTX Launches XRx-101, A New Program to Treat Coronavirus COVID-19 Infection

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, with late stage clinical programs, announces that it is...

Mar 02, 2020 05:25 pm ET

XORTX Announces First Tranche Closing of Non-Brokered Private Placement

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it has closed a first tranche of...

Jan 31, 2020 08:14 pm ET

XORTX Announces Re-Pricing of Private Placement

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease announces that it has re-priced its non-brokered private...

Sep 19, 2019 09:00 pm ET

XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN)

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease is pleased to share, in conjunction with Teijin Pharma Limited...

Sep 04, 2019 07:00 am ET

XORTX Highlights New Research on Polycystic Kidney Disease Awareness Day

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to highlight in conjunction with...

Aug 05, 2019 08:35 am ET

OTCQB Venture Company Investor Presentations Now Available for On-Demand Viewing

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

Aug 05, 2019 08:35 am ET

OTCQB Venture Company Investor Presentations Now Available for On-Demand Viewing

NEW YORK, Aug. 5, 2019 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the August 1, 2019 OTCQB Venture Company Conference are now available for on-demand viewing at VirtualInvestorConferences.com.

Jul 30, 2019 08:35 am ET

Live OTCQB Venture Company Investor Conference August 1st

Company executives will share vision and answer audience questions at VirtualInvestorConferences.com

Jul 30, 2019 08:35 am ET

Live OTCQB Venture Company Investor Conference August 1st

NEW YORK, July 30, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming Virtual lnvestor Conference, the leading proprietary investor conference series. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:15 AM ET, with the first live webcast at 9:30 AM ET, on Thursday, August 1st.

Jul 30, 2019 07:00 am ET

XORTX Announces Virtual Investor Conference Live Webcast

CALGARY, Alberta, July 30, 2019 /PRNewswire/ -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE: XRX; OTCQB: XRTXF; ANU1: FWB), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that Dr. Allen Davidoff, CEO, will be presenting at VirtualInvestorConferences.com (www.VirtualInvestorConferences.com) on August 1st, a live, interactive online event where investors are invited to ask the Company questions in real-time – see details below.

Jul 30, 2019 07:00 am ET

XORTX Announces Virtual Investor Conference Live Webcast

Jul 18, 2019 08:38 pm ET

XORTX Reports Annual & Special Meeting Results

Jul 15, 2019 07:00 am ET

XORTX Shares Nature Nephrology Review

Apr 29, 2019 05:09 pm ET

XORTX Provides Overview and Announces $5 Million Financing to Advance Clinical Trials

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, confirms that the Company has filed its audited financial...

Apr 16, 2019 10:55 am ET

XORTX Shares Findings of Diabetes Study in Youths Supporting High Uric Acid Advances Kidney Disease Progression

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, congratulates the TODAY study team and Dr. Petter Bjornstad on...

Mar 25, 2019 07:00 am ET

XORTX Shares Findings of New Diabetes Study Supporting Uric Acid as an Independent Risk Factor

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to highlight a recent and impactful finding by...

Mar 12, 2019 10:58 am ET

IIROC Trade Resumption - XRX

VANCOUVER, March 12, 2019 /CNW/ - Trading resumes in:

Mar 12, 2019 10:51 am ET

XORTX Signs LOI for Co-Development and Licensing Agreement with Japan’s Teijin Pharma Limited

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that on March 11, 2019, the Company...

Mar 12, 2019 10:32 am ET

IIROC Trading Halt - XRX

VANCOUVER, March 12, 2019 /CNW/ - The following issues have been halted by IIROC:

Jan 28, 2019 07:00 am ET

XORTX to Present at NobleConXV Noble Capital Markets’ 15th Annual Investor Conference

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (PKD), is pleased to announce that Dr. Allen Davidoff, XORTX’s CEO...

Nov 26, 2018 05:00 pm ET

XORTX Receives FDA Response on Orphan Drug Designation Application

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (PKD), is pleased to announce that the Company along with its...

Nov 06, 2018 09:58 pm ET

XORTX Announces Appointment of CFO

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (“PKD”), is pleased to announce the appointment of James Fairbairn...

Oct 23, 2018 07:00 am ET

XORTX Announces Revision to Polycystic Kidney Disease Clinical Development Plan

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (“PKD”), is pleased to announce that the Company’s clinical...

Oct 15, 2018 07:00 am ET

XORTX Announces New Clinical Advisory Board Members

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the addition of two new members to the...

Sep 10, 2018 07:00 am ET

XORTX Announces Submission of Orphan Drug Designation Application

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company along with its...

Aug 13, 2018 07:00 am ET

XORTX Submits FDA pre-IND Meeting Documents

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company with its collaborative...

Jun 28, 2018 08:59 am ET

XORTX Reports on Annual Special Meeting and Provides Corporate Update

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide the results of the Company’s annual and...

Jun 08, 2018 07:00 am ET

XORTX Announces Filing of FDA pre-IND Meeting Request Letter

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the Company along with Cato Clinical...

Jun 06, 2018 05:38 pm ET

XORTX to Commence Trading on the OTCQB Venture Market

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company’s shares have been...

May 08, 2018 07:00 am ET

XORTX Appoints Chairman

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Bruce Rowlands, a director of XORTX...

Apr 19, 2018 07:00 am ET

XORTX Announces PKD Foundation Collaboration

CALGARY, Alberta, April 19, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) is pleased to announce that the PKD Foundation has recognized XORTX as a leader in advancing the development of treatments for progressive...

Mar 20, 2018 09:24 pm ET

XORTX Announces Issuance of Stock Options

CALGARY, Alberta, March 20, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has issued an aggregate of 2,250,000...

Feb 27, 2018 07:30 am ET

XORTX Therapeutics Provides Corporate Update

CALGARY, Alberta, Feb. 27, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide this corporate update.

Feb 22, 2018 07:30 am ET

XORTX Therapeutics Appoints Dave Matthews CFO

CALGARY, Alberta, Feb. 22, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Dave Matthews...

Jan 29, 2018 07:30 am ET

XORTX Therapeutics Announces Appointment of Allan Williams and Paul Van Damme

CALGARY, Alberta, Jan. 29, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX), a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the appointment of Allan Williams and Paul Van...

Ad blocking detected

XORTX Therapeutics Inc. (V:XRX)

Business Focus: Bio Therapeutic Drugs